These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

102 related items for PubMed ID: 1913509

  • 1. The use of prophylactic eye drops during high-dose cytosine arabinoside therapy.
    Higa GM, Gockerman JP, Hunt AL, Jones MR, Horne BJ.
    Cancer; 1991 Oct 15; 68(8):1691-3. PubMed ID: 1913509
    [Abstract] [Full Text] [Related]

  • 2. Topical prophylaxis of conjunctivitis induced by high-dose cytosine arabinoside.
    Matteucci P, Carlo-Stella C, Di Nicola M, Magni M, Guidetti A, Marchesi M, Gianni AM.
    Haematologica; 2006 Feb 15; 91(2):255-7. PubMed ID: 16461314
    [Abstract] [Full Text] [Related]

  • 3. [Effects of the rational use of corticosteroids eye drops for the prevention of ocular toxicity in high-dose cytosine arabinoside therapy].
    Itoh M, Aoyama T, Yamamura Y, Nakajima K, Nakamura K, Kotaki H, Matsuyama T, Saitoh T, Kami M, Chiba S, Hirai H, Yazaki Y, Iga T.
    Yakugaku Zasshi; 1999 Mar 15; 119(3):229-35. PubMed ID: 10198598
    [Abstract] [Full Text] [Related]

  • 4. Comparison of the prophylactic effects of 2-deoxycytidine and prednisolone for high-dose intravenous cytarabine-induced keratitis.
    Lazarus HM, Hartnett ME, Reed MD, Murphy BF, Lass JH.
    Am J Ophthalmol; 1987 Nov 15; 104(5):476-80. PubMed ID: 3314526
    [Abstract] [Full Text] [Related]

  • 5. The use of prophylactic eye drops during high-dose cytosine arabinoside therapy.
    Gococo KO, Lazarus HM, Lass JH.
    Cancer; 1992 Jun 01; 69(11):2866-7. PubMed ID: 1571919
    [No Abstract] [Full Text] [Related]

  • 6. Anterior uveitis associated with high-dose cytosine arabinoside.
    Fintelmann RE, Qian Y, Skalet A, Jeng BH.
    Ocul Immunol Inflamm; 2010 Dec 01; 18(6):485-7. PubMed ID: 20887203
    [Abstract] [Full Text] [Related]

  • 7. Prophylactic treatment for cytosine arabinoside-induced keratoconjunctivitis.
    Patel AK, Sheehan W, Jenkins A, Lane C, Kell J.
    Int Ophthalmol; 2011 Jun 01; 31(3):191-5. PubMed ID: 21424238
    [Abstract] [Full Text] [Related]

  • 8. An in vitro method which assesses corneal epithelial toxicity due to antineoplastic, preservative and antimicrobial agents.
    Lazarus HM, Imperia PS, Botti RE, Mack RJ, Lass JH.
    Lens Eye Toxic Res; 1989 Jun 01; 6(1-2):59-85. PubMed ID: 2488034
    [Abstract] [Full Text] [Related]

  • 9. Paraplegia following intrathecal cytosine arabinoside.
    Wolff L, Zighelboim J, Gale RP.
    Cancer; 1979 Jan 01; 43(1):83-5. PubMed ID: 282937
    [Abstract] [Full Text] [Related]

  • 10. Cytosine arabinoside-induced vasculitis.
    Ahmed I, Chen KR, Nakayama H, Gibson LE.
    Mayo Clin Proc; 1998 Mar 01; 73(3):239-42. PubMed ID: 9511781
    [Abstract] [Full Text] [Related]

  • 11. [A case of complete remission from acute myelogenous leukemia in second relapse achieved using an intermediate-dose cytosine arabinoside (ID Ara-C) regimen].
    Yoshida M, Owada N, Sasaki R, Sakamoto S, Miura Y.
    Gan To Kagaku Ryoho; 1986 Jan 01; 13(1):143-6. PubMed ID: 3455805
    [Abstract] [Full Text] [Related]

  • 12. [Effectiveness and toxicity of high-dosage Ara-C. Clinical observations in 10 cases and review of the literature].
    Morant R, Hofmann V, Honegger HP, Gmür J, Fehr J, Sauter C.
    Schweiz Med Wochenschr; 1986 Oct 11; 116(41):1415-9. PubMed ID: 3466340
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Low-dose cytosine arabinoside in acute non-lymphoblastic leukemia.
    Kumar L, Kochupillai V, Dua H.
    Cancer; 1989 Feb 01; 63(3):415-8. PubMed ID: 2912519
    [Abstract] [Full Text] [Related]

  • 15. High-dose cytarabine as salvage therapy for relapsed or refractory acute myeloid leukemia--is more better or more of the same?
    Wolach O, Itchaki G, Bar-Natan M, Yeshurun M, Ram R, Herscovici C, Shpilberg O, Douer D, Tallman MS, Raanani P.
    Hematol Oncol; 2016 Mar 01; 34(1):28-35. PubMed ID: 25689584
    [Abstract] [Full Text] [Related]

  • 16. Dexamethasone/Povidone Eye Drops versus Artificial Tears for Treatment of Presumed Viral Conjunctivitis: A Randomized Clinical Trial.
    Pinto RD, Lira RP, Abe RY, Zacchia RS, Felix JP, Pereira AV, Arieta CE, de Castro RS, Bonon SH.
    Curr Eye Res; 2015 Sep 01; 40(9):870-7. PubMed ID: 25310347
    [Abstract] [Full Text] [Related]

  • 17. Handling punctate keratitis resulting from systemic cytarabine.
    Friedland S, Loya N, Shapiro A.
    Ann Ophthalmol; 1993 Aug 01; 25(8):290-1. PubMed ID: 8239322
    [Abstract] [Full Text] [Related]

  • 18. Modulation of cytosine arabinoside (ara-C) and high-dose ara-C in acute leukemia.
    Zittoun R, Marie JP, Zittoun J, Marquet J, Haanen C.
    Semin Oncol; 1985 Jun 01; 12(2 Suppl 3):139-43. PubMed ID: 3859928
    [No Abstract] [Full Text] [Related]

  • 19. Is there a relationship between cytarabine pharmacokinetics and keratitis?--A case report.
    Boos J, Bömelburg T, Gerding H, Jürgens H.
    Int J Clin Pharmacol Ther Toxicol; 1993 Dec 01; 31(12):593-6. PubMed ID: 8314360
    [Abstract] [Full Text] [Related]

  • 20. Post-remission therapy of adult acute myeloid leukemia: high dose cytosine-arabinoside versus other consolidation regimens.
    Zeremski V, Savić A.
    Med Pregl; 2014 Dec 01; 67(3-4):83-90. PubMed ID: 24961049
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.